T. Rowe Price Associates
GENB

T. Rowe Price Associates’s Generate Biomedicines GENB Stock Holding History

T. Rowe Price Associates’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Buy
+2,109,633
New +$25.8M ﹤0.01% 974

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
NC
Nvidia Corp Santa Clara, California $18.4B AUM 362.26% 1-Year Est. Return

T. Rowe Price Associates's GENB Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in Generate Biomedicines (GENB) in Q1 2026: 2,109,633 shares worth $26.4M. The stake represents ﹤0.01% of the portfolio and ranks #974 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

  • T. Rowe Price Associates held 2,109,633 shares of Generate Biomedicines worth $26.4M as of Q1 2026.
  • Generate Biomedicines was a new T. Rowe Price Associates position in Q1 2026.
  • Generate Biomedicines made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #974 holding.
  • 57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.